Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, retaining the price target of $9.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Unicycive Therapeutics. The company is actively addressing concerns raised by the FDA regarding a manufacturing compliance issue, and a meeting with the FDA is anticipated soon to discuss the regulatory path forward for their drug, oxylanthanum carbonate (OLC). Despite the setback, there are no issues with the drug’s safety or efficacy, and the FDA has positively received the data package, leading to optimism about its approval.
Furthermore, Unicycive is well-positioned financially, with a cash runway extending into the second half of 2026, and a committed capital of $102 million from investors that will be triggered upon OLC’s approval. The company has a commercial team ready to launch the drug immediately after approval, which supports the potential for significant sales growth. The valuation of the stock is based on a risk-adjusted net present value analysis, projecting substantial revenues through 2031, resulting in a 12-month price target of $9.00 per share.